This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freeman, J. W. Articles by Busch, H. Search for Related Content PubMed PubMed Citation Articles by Freeman, J. W. Articles by Busch, H.

Prognostic Significance of Proliferation Associated Nucleolar Antigen P120 in Human Breast Carcinoma¹

Department of Surgery, Division of General Surgery, and Department of Microbiology and Immunology and Lucille Markey Cancer Center, University of Kentucky Medical Center, Lexington, Kentucky 40536 [J. W. F., P. M., V. B., N. S.]; American Red Cross, Southeastern Michigan Regional Blood Services, Detroit, Michigan 48232 [H. O.]; Michigan Cancer Foundation, Meyer L. Prentis Cancer Center, Detroit, Michigan 48201 [T. M.]; and Department of Pharmacology, Baylor College of Medicine, Houston, Texas 77030 [R. K. B., H. B.]

Nucleolar antigen P120 is detected in rapidly proliferating cells but not in normal resting cells or in many benign and slowly growing malignant tumors. The objective of the study was to determine whether the expression of P120 in breast cancer correlated with histopathological or biological properties associated with prognosis. In this retrospective study, 120 primary breast tumors were analyzed for P120; 114 of these tumors were also stained for the erbB-2 protein. Immunopositive staining was correlated with patient survival, nodal status, estrogen receptor levels, and number of mitoses. Sixty-nine % (83 of 120) of the tumors were positive for P120; 25% (28 of 114) stained positively for erbB-2. Of the 28 erbB-2 positive tumors 26 were also positive for the P120 protein. Forty-six % (55 of 120) of the specimens were from patients who later died from recurrent breast cancer; P120 was detected in 89% (49 of 55) of these specimens. In 52% of the survivors the P120 protein was also expressed. P120 negative tumors were highly correlative with survival (P = 0.0001); 84% (32 of 37) of patients with P120 negative tumors survived more than 7 years without evidence of recurrent disease. Multivariate analysis showed that the worst prognosis was for patients who had tumor positive nodes and expressed P120 (P = 0.0001); death occurred in 73% (30 of 41) of these patients. For the node negative patients who did not express P120, 5-year survival was 90% (19 of 21 patients); 5-year survival for the node negative patients who expressed P120 was significantly less (67%; 28 of 42 patients). Patients with P120 negative tumors had a good prognosis, irrespective of their nodal status. In this group, survival of node negative patients was 86% (18 of 21) and for those with positive nodes survival was 82% (13 of 16). A poor prognosis was found for patients with intense erbB-2 stained tumors (5 of 7 patients died). Weak staining of erbB-2 tumors (21 specimens) was not correlated with patient survival. Compared to P120 negative tumors, P120 positive tumors had greater numbers of mitoses (9.06 versus 6.65) and an almost 2-fold increase in the occurrence of positive nodes (one of every 4.67 versus one of every 8.81). The number of P120 positive tumors was greater in estrogen receptor positive tumors (75%) than in estrogen negative tumors (54%).

These studies suggest that antigen P120 may be a prognostic marker in breast cancer and could be used along with other parameters such as nodal status to assess the prognostic outcome of breast cancer patients.

¹ These studies were supported by USPHS-National Cancer Institute Grant 1 R29-CA49633 and American Cancer Society Grant IN-163.

² To whom requests for reprints should be addressed, at the Lucille Markey Cancer Center, University of Kentucky Medical Center, Lexington, KY 40536-0093.

Received 11/ 6/90. Accepted 1/31/91.

This article has been cited by other articles:

				A. Khanna-Gupta, H. Sun, T. Zibello, L. Lozovatsky, P. K. Ghosh, D. C. Link, M. L. McLemore, and N. Berliner p120 nucleolar-proliferating antigen is a direct target of G-CSF signaling during myeloid differentiation J. Leukoc. Biol., May 1, 2006; 79(5): 1011 - 1021. [Abstract] [Full Text] [PDF]

				G. Sato, Y. Saijo, B. Uchiyama, N. Kumano, S.-i. Sugawara, S. Fujimura, M. Sato, M. Sagawa, K. Ohkuda, K. Koike, et al. Prognostic Value of Nucleolar Protein p120 in Patients With Resected Lung Adenocarcinoma J. Clin. Oncol., September 1, 1999; 17(9): 2721 - 2721. [Abstract] [Full Text] [PDF]

				J. Amann, V. J. Kidd, and J. M. Lahti Characterization of Putative Human Homologues of the Yeast Chromosome Transmission Fidelity Gene, CHL1 J. Biol. Chem., February 7, 1997; 272(6): 3823 - 3832. [Abstract] [Full Text] [PDF]